Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 6, 2016
Event: Regulation FD Disclosure regarding the top-line results of the second Phase 3 clinical trial for DEXTENZA® in the treatment of allergic conjunctivitis.
Financial Metrics
This filing is a current report regarding a clinical trial update and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the announcement of clinical trial results for the Company's lead product candidate, DEXTENZA®. No financial material changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Management Commentary
- Clinical Update: The Company issued a press release (Exhibit 99.1) announcing top-line results from its second Phase 3 trial for DEXTENZA® for allergic conjunctivitis.
- Investor Communication: Management scheduled a conference call and webcast for June 6, 2016, at 8:30 am Eastern Time to discuss the results. Presentation slides are included as Exhibit 99.2.
- Legal Disclaimer: The information in this Form 8-K and its exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific top-line statistical results of the second Phase 3 DEXTENZA® trial by reviewing the attached Press Release (Exhibit 99.1).
- Review the detailed data and management commentary in the slide presentation (Exhibit 99.2) released on June 6, 2016.
- Confirm the impact of these clinical results on the Company's regulatory pathway and potential commercialization timeline for DEXTENZA®.